Novel Factor-Based Symptom Scores in Treatment Resistant Schizophrenia: Implications for Clinical Trials

[1]  J. Kane,et al.  Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial , 1989, Psychopharmacology.

[2]  C. Lançon,et al.  Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS) , 2000, Schizophrenia Research.

[3]  S. Klimidis,et al.  The three-syndrome model of schizophrenia: Meta-analysis of an artefact , 1999, Schizophrenia Research.

[4]  C. Adams,et al.  Content and quality of 2000 controlled trials in schizophrenia over 50 years , 1998, BMJ.

[5]  P. Cuesta,et al.  Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia , 1998, Psychiatry Research.

[6]  Philip D. Harvey,et al.  Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale , 1996, Biological Psychiatry.

[7]  W A Hargreaves,et al.  Clozapine eligibility among state hospital patients. , 1996, Schizophrenia bulletin.

[8]  R. Neufeld,et al.  Variability in BPRS definitions of positive and negative symptoms , 1995, Schizophrenia Research.

[9]  N. Andreasen,et al.  A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. , 1995, Archives of general psychiatry.

[10]  Larry Hatcher,et al.  A Step-by-Step Approach to Using the SAS System for Factor Analysis and Structural Equation Modeling , 1994 .

[11]  S Pollack,et al.  Cerebral morphometry and clozapine treatment in schizophrenia. , 1994, The Journal of clinical psychiatry.

[12]  W. Carpenter,et al.  Domains of Psychopathology: An Approach to the Reduction of Heterogeneity in Schizophrenia , 1994, The Journal of nervous and mental disease.

[13]  M. Davidson,et al.  Predictors of Response to Neuroleptic Treatment in Schizophrenia , 1993 .

[14]  Lieberman Ja.  Prediction of outcome in first-episode schizophrenia. , 1993 .

[15]  J. Lieberman.  Prediction of outcome in first-episode schizophrenia. , 1993, The Journal of clinical psychiatry.

[16]  N C Andreasen,et al.  The Distinction of Positive and Negative Symptoms , 1991, British Journal of Psychiatry.

[17]  I. Liberzon,et al.  Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia. , 1991, Psychopathology.

[18]  N. Schooler,et al.  Are Biochemical Markers for Treatment‐Resistant Schizophrenia State Dependent or Traits? , 1990, Clinical neuropharmacology.

[19]  N. Andreasen.  The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[20]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[21]  J. Overall.  The brief psychiatric rating scale (BPRS) : Recent developments in ascertainment and scaling. Introduction , 1988 .

[22]  R. Toyoshima,et al.  Treatment resistant chronic psychopathology and CT scans in schizophrenia , 1987, Acta psychiatrica Scandinavica.

[23]  P. Wender,et al.  Treatment of attention deficit disorder with DL-phenylalanine , 1985, Psychiatry Research.

[24]  J. Overall,et al.  Applied multivariate analysis , 1983 .

[25]  M. F. Fuller,et al.  Practical Nonparametric Statistics; Nonparametric Statistical Inference , 1973 .

[26]  W. J. Conover,et al.  Practical Nonparametric Statistics , 1972 .

[27]  Jonathan O. Cole,et al.  High Dose Chlorpromazine Therapy in Chronic Schizophrenia: Report of National Institute of Mental Health—Psychopharmacology Research Branch Collaborative Study Group , 1968 .